Safety of Luspatercept in Korean Patients With Blood Disorders
Studies real-world safety of luspatercept in Korean adults with myelodysplastic syndrome or beta thalassemia.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
- Status
- Recruiting
- People taking part
- 104 people, planned
- Started
- 25 Mar 2024
- Expected to end
- 21 Dec 2027
- Type of study
- Observational
- Treatments tested
- Luspatercept
- Record updated
- 6 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Korea with myelodysplastic syndrome (MDS) or beta thalassemia who will be treated with luspatercept as approved in Korea. It watches how safe the drug is in real life.
- Age
- 19 years or older
- Sex
- All sexes can join.
Main reasons for not taking part
- Luspatercept prescribed for a use not approved in the Republic of Korea
- Luspatercept is contraindicated, as set out in the Korean prescribing information
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult participants 19 years of age or older
- Participants who will be treated with luspatercept according to the approved label in the Republic of Korea
- Participants who sign the informed consent form
Who cannot take part
- Participants for whom luspatercept is contraindicated as clarified in the Korean prescribing information approved by the Ministry of Food and Drug Safety
- Participants who are prescribed luspatercept for therapeutic indications not approved in the Republic of Korea
Where in South Korea
- Novotech Laboratory Korea Co., Ltd.Seoul, South KoreaContact: South Korea Generic Country, Site 0002Taking people
- SeoulHospital not named in the registryNo longer taking part
About the trial
What the trial wants to find out
The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.
The group in the trial
- Participants with myelodysplastic syndrome or beta thalassemia who will begin luspatercept treatment
Treatment: Luspatercept
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia
- Plain-language title
- Safety of Luspatercept in Korean Patients With Blood DisordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2024